Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2018

View Archived Issues

Armis Biopharma's Ximycin designated as QIDP by FDA

Sumitomo Dainippon Pharma highlights progress of third quarter of fiscal 2017

First patient treated in phase III study of BeiGene's tislelizumab

Dermira begins phase IIb study of lebrikizumab in moderate to severe atopic dermatitis

Preclinical data presented for adipoRon in cholangiocarcinoma

Sage Therapeutics' SAGE-217 improves sleep efficiency and sleep time in model of insomnia

FDA gives Protalix Biotherapeutics' PRX-102 fast track designation

Oncolix sponsoring evaluation of Prolanta for other gynecological cancers

Cara Therapeutics begins pivotal phase III study of Korsuva in CKD-associated pruritus

Acasti initiates TRILOGY trials of CaPre in patients with severe hypertriglyceridemia

Vertex selects VX-659 and VX-445 to advance into phase III cystic fibrosis triple combination trials

Phase III U.S. study of transdermal patch for schizophrenia meets primary endpoint

IDO1 as an indicator of poor outcome in anal squamous cell carcinoma

First patient treated in clinical study of ONC-201 in children with H3 K27M mutant glioma

AbGenomics' neihulizumab granted orphan drug status in U.S. for aGvHD

Vaxart's oral influenza tablet vaccine demonstrates reduction in rate of influenza infection

Medshine Discovery patents new PPAR agonists

Gemphire initiates phase IIa trial of gemcabene for pediatric NAFLD

Seattle Genetics enters definitive merger agreement to acquire Cascadian Therapeutics

Cadila Healthcare divulges novel RORgamma inverse agonists

Bristol-Myers Squibb discloses PD-1/PD-L1 interaction inhibitors

Japanese researchers present compounds for Parkinson's disease

Galecto Biotech discovers galectin inhibitors

AstraZeneca initiates phase IIa study of AZD-9567 in rheumatoid arthritis

Lanreotide effective for prolonged control of carcinoid syndrome symptoms

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...